The U.S. Food and Drug Administration has granted approval to Nuvation Bio for Ibtrozi (taletrectinib), an oral medication targeting advanced ROS1-positive non-small cell lung cancer (NSCLC). Clinical trials showed high response rates, particularly in patients naïve to prior tyrosine kinase inhibitors, with durable responses lasting up to nearly four years. The approval adds a new therapeutic option amid existing treatments, albeit with safety warnings and mixed market reception.